Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News

Baxter Reinforces Commitment To Disparities In Care And Shares A New Vision

Baxter Healthcare Corporation announced its continued commitment to the hemophilia community to close the gap in hemophilia care and the company’s vision to pursue a bleed-free world for people living with this disorder on World Hemophilia Day. For more than 60 years, Baxter has been a dedicated partner to the hemophilia community and is committed […]

Life Sciences Firm Entegrion Lands Global Partner

Research Triangle Park, N.C. — Blood technologies company Entegrion is partnering with an Italian company to develop and commercialize Resusix, Entegrion’s freeze-dried human plasma. Under the deal, Kedrion Melville gains exclusive worldwide rights to commercialize Resusix. Entegrion, based in Research Triangle Park, will collaborate with Kedrion on clinical development of the product. Clinical trials are […]

FDA Accepts Biogen Idec’s License Application for First Long-Lasting Factor Therapy for Hemophilia B

WESTON, Mass.-Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has accepted the company`s Biologics License Application (BLA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B and granted the company a standard review timeline. Recombinant FIXFc is the first product candidate in […]

BioRx

BioRx Introduces National Physical Therapy Program

CINCINNATI, Ohio  - BioRx announced today the launch of a new physical therapy program to help patients, physicians, physical therapists, and health insurers manage the complications and costs of hemophilia-related joint damage. The program, called REBUILD, supports a patient’s physical therapy program at the local level. Under the direction of an experienced physical therapist for […]

NY Times: Dispute Develops Over Discount Drug Program

By: Andrew Pollack  When a private oncology practice in Memphis formed a partnership with a nearby hospital in late 2011, the organizations proclaimed that the deal would “transform cancer care” in the region. What they did not emphasize was that the deal would also create a windfall for them worth millions of dollars a year, […]

ATHN and The Hemophilia Alliance Announce Memorandum of Understanding

February 6, 2013  – The Hemophilia Alliance and the American Thrombosis and Hemostasis Network (ATHN) are pleased to announce they have entered into a Memorandum of Understanding to provide financial assistance to ATHN in support of the ATHN Data Quality Counts program for Hemophilia Treatment Centers (HTCs) across the country. Funding from the Hemophilia Alliance […]

PSI and Bayer Healthcare Introduce Co-Pay/Co-Insurance Pilot Program

Midlothian, VA and Wayne, NJ –January 24, 2013 – Patient Services, Inc. (PSI) and Bayer HealthCare are pleased to announce the Kogenate® FS Co-pay/Co-Insurance Assistance Pilot Program. The pilot program is funded by Bayer to help qualified Kogenate® FS patients with their out-of-pocket payments. What is offered through the pilot program? PSI will administer and […]

Biogen Idec Submits Application to FDA for First Long-Lasting Factor IX Therapy For Hemophilia B

WESTON, Mass.– Today, Biogen Idec announced the company recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B. rFIXFc is the first product candidate in a new class of long-lasting clotting factor therapies that […]

Incivek (telaprevir) In Combination with Drugs Peginterferon Alfa and Ribavirin (Incivek Combination Treatment): Drug Safety Communication – Serious Skin Reactions

AUDIENCE: Internal Medicine, Gastroenterology, Dermatology ISSUE: FDA received reports of serious skin reactions, some fatal, in patients taking the hepatitis C drug Incivek (telaprevir) in combination with the drugs peginterferon alfa and ribavirin (Incivek combination treatment). Some patients died when they continued to receive Incivek combination treatment after developing a worsening, or progressive rash and […]

Pfizer Hemophilia: The Way You Log Is About To Change

Pfizer Hemophilia is excited to announce the launch of its first mobile logging tool, HemMobile™, a free mobile app designed to help hemophilia patients and caregivers using any factor replacement product log infusions and bleeds and stay aware of general health and wellness. Developed with input from members of the bleeding disorders community, HemMobile™ was […]

Page 5 of 1312345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community